Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
Almost a week after the Apple faithful collectively gasped at the first evidence that the iPhone’s red “end call” button might soon be vacating its center position to take up residence one column to the right, it looks like it might have been mostly a false alarm.
Meta is under scrutiny for the way it has moderated reproductive health content. Women's health advocates say the social media giant has allowed male health content to flow more freely than content geared toward women and gender diversity.
Lynn Martin, president of the New York Stock Exchange, talks to Cheddar News about the bounceback of the IPO market, the future of artificial intelligence, and the strength NYSE continues to command in the world of investing.
